奥瑞珠单抗治疗多发性硬化后引发机化性肺炎：病例报告。
Organizing pneumonia following ocrelizumab use in a patient with multiple sclerosis: A case report.
机构信息
Clinic of Chest Diseases, İstanbul Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, İstanbul, Türkiye.
Clinic of Chest Diseases, Başakşehir Çam and Sakura City Hospital, İstanbul, Türkiye.
出版信息
Tuberk Toraks. 2023 Mar;71(1):107-111. doi: 10.5578/tt.20239913.
Ocrelizumab is an anti-CD20 monoclonal antibody used in the treatment of primary progressive and relapsing multiple sclerosis (MS). Although cases of organizing pneumonia have been reported in association with other antiCD20 agents such as rituximab, there is insufficient data in the literature on Ocrelizumab-associated lung involvement. Herein, we present a case of organizing pneumonia in a 37-year-old female patient with multiple sclerosis following Ocrelizumab use.
奥瑞珠单抗是一种用于治疗原发性进行性和复发性多发性硬化症（MS）的抗 CD20 单克隆抗体。虽然已经报道了与其他抗 CD20 药物（如利妥昔单抗）相关的机化性肺炎病例，但关于奥瑞珠单抗相关肺受累的文献数据不足。在此，我们报告了一例奥瑞珠单抗治疗后发生机化性肺炎的 37 岁女性多发性硬化症患者。
Zotero 插件